Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
| Market Capitalization | $37.6773 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.078 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.05 |
| EBITDA | |
| Profit Margin | -2.7516 |
| Operating Margin TTM | -2.7859 |
| Return on Assets TTM | -0.3279 |
| Return on Equity TTM | -0.6029 |
| Revenue TTM | 1,749.899 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2019-12-31 | 0.25 | |||
| 2020-12-31 | 0.2 | 1,325.704 | ||
| 2021-12-31 | 2.5 | 4,351.532 | ||
| 2022-12-31 | 61 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2019-12-31 | 341.98 | 377.66 | 359.26 | 0 | 401.8 | |
| 2020-12-31 | 7,144.195 | 7,272.467 | 425.72 | 0 | 8,051.013 | |
| 2021-12-31 | 8,914.457 | 9,043.4 | 735.909 | 0 | 13,065.033 | |
| 2022-12-31 | 9,289.16 | 9,541.86 | 1,874.42 | 0 | 16,618.27 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2019-12-31 | -657.262 | -100.829 | 586.258 | 341.984 | ||
| 2020-12-31 | -1,029.501 | -1,046.408 | 6,802.211 | 341.984 | 7,144.195 | |
| 2021-12-31 | -4,090.752 | -3,361.673 | 1,770.262 | 7,144.195 | 8,914.457 | |
| 2022-12-31 | -4,815.044 | -3,300.32 | 374.7 | 8,914.457 | 9,289.156 |